According to the World Health Organization (WHO), the vaccine developed by the University of Oxford against Kovid-19 in partnership with AstraZeneca can be applied in areas where there are new forms of coronovirus, as well as people over 65 and comrades In people also. )) This Wednesday (10).
The document prepared by the Strategic Advisory Group of Experts (SAGE) states that countries should prioritize the first phase of vaccination with health professionals and the elderly with and without comradeship.
The document published by WHO stated, “Protecting the elderly will have a greater impact on public health in terms of reducing the number of deaths.”
The document highlights that there is little or no data from clinical trials in children and adolescents under 18 years of age. Therefore, applications for 18 years or longer are recommended.
Although recent studies suggest that the Oxford vaccine is less effective against the South African strain, the WHO stressed that vaccination variants can be used against it.
A healthcare professional extracted a bottle of Oxford vaccine for application in Brighton, southern England, on 26 January. – Photo: Ben Stancel / AFP
Another WHO recommendation on Oxford Vaccine concerns administration: It should be administered in two doses, with an interval of 8 to 12 weeks. After the application of two doses, there is no need for a booster dose.
The same vaccine should be administered in both doses, as data on combined use are not yet available.
In addition, if the person has had another vaccine (for any other disease), they will have to wait 14 days to receive the Kovid-19 vaccine.
In the first week of February, scientists at Oxford University reported in a preliminary study that A. Vaccines may have the potential to reduce transmission of new coronaviruses by up to 67.6%.
Video: First results of the Oxford vaccine. eiros resivacina